Decipher Score Linked to Prostate Cancer Progression

A study found higher genomic risk scores correlate with pathological progression in California prostate cancer patients.

Updated on Sept. 22, 2026 in Men’s Health

Isometric editorial illustration of a glass specimen vial and microscope lens, representing genomic cancer research. — A new University of California, San Francisco study finds that high genomic risk scores are significant predictors of prostate cancer progression. AI Illustration. Upload story photo >

Live Poll

Do you believe genomic testing helps patients better manage long-term health surveillance and treatment decisions?

Research published on January 31, 2026, linked high Decipher genomic risk scores to an increased likelihood of major disease progression. The study analyzed 486 men enrolled in a University of California, San Francisco outcomes database.

Why it matters

Genomic testing, such as the Decipher RNA assay, may provide physicians with a more precise way to tailor surveillance intensity for patients diagnosed with prostate cancer. This could assist in identifying which individuals require closer monitoring or earlier intervention.

The study utilized the Decipher genomic classifier, with scores of 0.6 or higher identified as high risk. Investigators observed that 12% of the 486 participants met this high-risk threshold during the 78-month median follow-up period.

The players

University of California, San Francisco

This public research university operates the outcomes database used by investigators to conduct the prostate cancer study.

The details

Researchers evaluated men who underwent at least two biopsies and Decipher testing, finding that elevated genomic risk scores were significant predictors of disease progression. These findings were notably impactful given that 78% of the cohort initially presented with Gleason grade group 1 disease.

January 31, 2026: Study published online in European Urology Oncology.
September 22, 2026: Article reporting study findings published.

Health Landscape

The findings mark a shift in how genomic markers are integrated into long-term patient monitoring strategies for localized prostate cancer. This research validates the potential for utilizing whole-transcriptome RNA assays to refine treatment pathways beyond standard clinicodemographic factors.

Patients currently on active surveillance for prostate cancer may consult their urologists about whether genomic testing is appropriate for their specific case. This diagnostic information could lead to more personalized monitoring schedules rather than uniform check-up intervals.

The takeaway

Genomic profiling offers a valuable tool for identifying aggressive disease markers in patients who appear low-risk based on standard biopsy results. Patients should discuss the implications of their personal Decipher scores with their oncology team to optimize their surveillance strategy.